Zomedica Announces Expansion of Market Opportunity for TRUFORMA(R) Diagnostic Platform with Launch of Three New Assays for Commonly Performed Diagnostic Tests for Canine Gastrointestinal Disease

ANN ARBOR, MI / ACCESSWIRE / December 18, 2023 / Zomedica Corp. (NYSE American:ZOM) (“Zomedica” or the “Company”), a veterinary health company offering point-of-care diagnostics and therapeutic products for equine and companion animals, today announced the commercial launch of three new assays: Canine Pancreatic Lipase (cPL), Cobalamin (B12) and Folate, for the TRUFORMA® In-Clinic Biosensor Testing Platform.

“Some of the most common patients a veterinarian sees are dogs presenting non-infectious Gastrointestinal disease signs, like vomiting and diarrhea,” said Larry Heaton, Zomedica’s Chief Executive Officer. “Knowing there is such a high need for a quick diagnosis, we are pleased to offer three of the most common assays for these cases: Canine Pancreatic Lipase (cPL), Cobalamin (B12), and Folate, to help diagnose pancreatitis and irritable bowel disease (IBD), respectively. We believe through these assays we can help veterinarians produce better outcomes for pets and pet parents by providing faster diagnostic solutions, while also streamlining their workflow and increasing practice profitability.”

“Our cPL assay is a sandwich immunoassay that uses bulk acoustic wave (BAW) technology to yield truly quantitative results with high precision, enabling veterinarians to confidently diagnose pancreatitis and monitor the response to therapy within minutes,” said Ashley Wood, PhD, Zomedica’s Vice President of Research & Development. “For cPL, veterinarians have historically needed to choose between a rapid in-clinic diagnostic and a high-quality reference lab test which typically meant waiting for results until at least the next day. The TRUFORMA cPL test delivers reference lab quality results at the point of care.

“In addition to cPL, since Cobalamin (B12) and Folate are typically run together, we are offering these assays together in one cartridge, our first ever multiplexed assay on the TRUFORMA platform. We believe that having these test results at the point of care will enable veterinarians to make decisions and offer appropriate treatment to patients before they leave the clinic,” concluded Dr. Wood.

The TRUFORMA cPL cartridge is available for shipping now from Zomedica, through either its myZomedica online portal or directly through Zomedica Customer Service. The combination Cobalamin & Folate cartridge will be available for shipping on or around December 23, 2023.

For more information on Zomedica please visit www.zomedica.com.

About Zomedica

Based in Ann Arbor, Michigan, Zomedica (NYSE American:ZOM) is a veterinary health company creating diagnostic and therapeutic products for horses, dogs, and cats by focusing on the unmet needs of clinical veterinarians. Zomedica’s product portfolio includes innovative diagnostics and medical devices that emphasize patient health and practice health. Zomedica’s mission is to provide veterinarians the opportunity to increase productivity and grow revenue while better serving the animals in their care. For more information, visit zomedica.com.

Follow Zomedica

• Email Alerts: http://investors.zomedica.com
• LinkedIn: https://www.linkedin.com/company/zomedica
• Facebook: https://m.facebook.com/zomedica
• Twitter: https://twitter.com/zomedica
• Instagram: https://www.instagram.com/zomedica_inc

Investor Contact:

Zomedica Investor Relations

investors@zomedica.com

1-734-369-2555

Cautionary Statement Regarding Forward-Looking Statements – Safe Harbor

Except for statements of historical fact, this news release contains certain “forward-looking information” or “forward-looking statements” (collectively, “forward-looking information”) within the meaning of applicable securities law. Forward-looking information is frequently characterized by words such as “plan”, “expect”, “project”, “intend”, “believe”, “anticipate”, “estimate” and other similar words, or statements that certain events or conditions “may” or “will” occur and include statements relating to our expectations regarding future results. Although we believe that the expectations reflected in the forward-looking information are reasonable, there can be no assurance that such expectations will prove to be correct. We cannot guarantee future results, performance, or achievements. Consequently, there is no representation that the actual results achieved will be the same, in whole or in part, as those set out in the forward-looking information.

Forward-looking information is based on the opinions and estimates of management at the date the statements are made, including assumptions with respect to economic growth, demand for the Company’s products, the Company’s ability to produce and sell its products, sufficiency of our budgeted capital and operating expenditures, the satisfaction by our strategic partners of their obligations under our commercial agreements, our ability to realize upon our business plans and cost control efforts and the impact of COVID-19 on our business, results and financial condition.

Our forward-looking information is subject to a variety of risks and uncertainties and other factors that could cause actual events or results to differ materially from those anticipated in the forward-looking information. Some of the risks and other factors that could cause the results to differ materially from those expressed in the forward-looking information include, but are not limited to: the outcome of clinical studies, the application of generally accepted accounting principles, which are highly complex and involve many subjective assumptions, estimates, and judgments, uncertainty as to whether our strategies and business plans will yield the expected benefits; uncertainty as to the timing and results of development work and verification and validation studies; uncertainty as to the timing and results of commercialization efforts, as well as the cost of commercialization efforts, including the cost to develop an internal sales force and manage our growth; uncertainty as to our ability to successfully integrate acquisitions; uncertainty as to our ability to supply products in response to customer demand; uncertainty as to the likelihood and timing of any required regulatory approvals, and the availability and cost of capital; the ability to identify and develop and achieve commercial success for new products and technologies; veterinary acceptance of our products; competition from related products; the level of expenditures necessary to maintain and improve the quality of products and services; changes in technology and changes in laws and regulations; our ability to secure and maintain strategic relationships; performance by our strategic partners of their obligations under our commercial agreements, including product manufacturing obligations; risks pertaining to permits and licensing, intellectual property infringement risks, risks relating to any required clinical trials and regulatory approvals, risks relating to the safety and efficacy of our products, the use of our products, intellectual property protection, risks related to the COVID-19 pandemic and its impact upon our business operations generally, including our ability to develop and commercialize our products, and the other risk factors disclosed in our filings with the SEC and under our profile on SEDAR at www.sedar.com. Readers are cautioned that this list of risk factors should not be construed as exhaustive.

The forward-looking information contained in this news release is expressly qualified by this cautionary statement. We undertake no duty to update any of the forward-looking information to conform such information to actual results or to changes in our expectations except as otherwise required by applicable securities legislation. Readers are cautioned not to place undue reliance on forward-looking information.

SOURCE: Zomedica Corp.

View the original press release on accesswire.com